Nektar Therapeutics (NKTR) Receivables (2010 - 2025)

Nektar Therapeutics' Receivables history runs 16 years deep, the most recent figure standing at $1.0 million for Q4 2025.

• On a quarterly basis, Receivables fell 9.09% year-over-year to $1.0 million in Q4 2025; TTM through Dec 2025 was $1.0 million, a 9.09% decrease from a year earlier, with the FY2025 full-year figure at $1.0 million, down 9.09% from the prior year.
• Receivables advanced to $1.0 million in Q4 2025 per NKTR's latest filing, from $200000.0 in the prior quarter.
• Across five years, Receivables topped out at $30.2 million in Q1 2022 and bottomed at $200000.0 in Q3 2025.
• The 5-year median for Receivables is $3.6 million (2024), against an average of $10.9 million.
• Across the five-year window, Receivables tumbled 90.09% in 2023 and increased 20.77% in 2024, its largest moves.
• Year by year, Receivables stood at $23.9 million in 2021, then plunged by 72.04% to $6.7 million in 2022, then sank by 74.48% to $1.7 million in 2023, then sank by 35.48% to $1.1 million in 2024, then declined by 9.09% to $1.0 million in 2025.
• Per Business Quant, the three latest NKTR Receivables figures stand at $1.0 million (Q4 2025), $200000.0 (Q3 2025), and $1.1 million (Q4 2024).